Stryker (NYSE:SYK) Insider Sells $277,783.80 in Stock

Stryker Corporation (NYSE:SYK) insider Debra King sold 826 shares of the stock in a transaction on Tuesday, August 18th. The shares were sold at an average price of $336.30, for a total transaction of $277,783.80. Following the completion of the sale, the insider directly owned 6,210 shares of the company’s stock, valued at approximately $2,088,423. This trade represents a 11.74% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink.

Stryker Stock Performance

Shares of NYSE:SYK traded up $0.28 on Tuesday, hitting $331.96. 3,179,813 shares of the company were exchanged, compared to its average volume of 2,370,435. The company has a debt-to-equity ratio of 0.59, a quick ratio of 1.33 and a current ratio of 2.16. The company’s 50 day moving average price is $325.21 and its two-hundred day moving average price is $333.24. Stryker Corporation has a one year low of $281.00 and a one year high of $396.86. The firm has a market capitalization of $127.33 billion, a price-to-earnings ratio of 34.40, a PEG ratio of 2.16 and a beta of 0.76.

Stryker (NYSE:SYK) last posted its quarterly earnings results on Thursday, July 30th. The medical technology company reported $3.69 earnings per share for the quarter, topping analysts’ consensus estimates of $3.49 by $0.20. Stryker had a net margin of 14.43% and a return on equity of 23.63%. The firm had revenue of $6.59 billion for the quarter, compared to the consensus estimate of $6.58 billion. During the same quarter in the previous year, the company earned $3.13 earnings per share. The business’s revenue was up 9.4% compared to the same quarter last year. Stryker has set its FY 2026 guidance at 14.950-15.100 EPS. Research analysts expect that Stryker Corporation will post 15.02 earnings per share for the current year.

Stryker Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Friday, October 30th. Investors of record on Wednesday, September 30th will be paid a $0.88 dividend. The ex-dividend date of this dividend is Wednesday, September 30th. This represents a $3.52 annualized dividend and a yield of 1.1%. Stryker’s payout ratio is currently 36.48%.

Wall Street Analysts Forecast Growth

A number of research firms recently commented on SYK. Royal Bank Of Canada decreased their price target on Stryker from $435.00 to $420.00 and set an “outperform” rating on the stock in a research report on Friday, July 31st. Robert W. Baird set a $385.00 price objective on Stryker in a research report on Friday, May 1st. Needham & Company LLC cut their price target on Stryker from $454.00 to $418.00 and set a “buy” rating on the stock in a research note on Friday, May 1st. BMO Capital Markets began coverage on shares of Stryker in a research report on Wednesday, July 8th. They issued an “outperform” rating and a $369.00 price target on the stock. Finally, UBS Group started coverage on Stryker in a report on Tuesday, July 28th. They set a “buy” rating and a $400.00 price objective on the stock. One equities research analyst has rated the stock with a Strong Buy rating, seventeen have assigned a Buy rating and six have assigned a Hold rating to the company’s stock. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and a consensus price target of $386.28.

Institutional Inflows and Outflows

A number of hedge funds have recently added to or reduced their stakes in SYK. Brighton Jones LLC boosted its position in Stryker by 15.4% during the fourth quarter. Brighton Jones LLC now owns 4,564 shares of the medical technology company’s stock valued at $1,643,000 after purchasing an additional 609 shares during the last quarter. Schnieders Capital Management LLC. bought a new stake in shares of Stryker during the 2nd quarter worth approximately $205,000. Marshall Wace LLP raised its stake in shares of Stryker by 107.9% during the 2nd quarter. Marshall Wace LLP now owns 5,700 shares of the medical technology company’s stock worth $2,255,000 after purchasing an additional 77,831 shares in the last quarter. Nebula Research & Development LLC acquired a new stake in shares of Stryker in the 2nd quarter valued at approximately $219,000. Finally, HUB Investment Partners LLC bought a new position in shares of Stryker in the second quarter valued at $253,000. Institutional investors own 77.09% of the company’s stock.

About Stryker

Stryker Corporation is a global medical technology company that designs, manufactures and markets a broad range of products and services for use in hospitals, surgeons’ offices and other healthcare facilities. Its primary business activities span orthopedics (including joint replacement implants, trauma and extremities products), surgical equipment and operating room technologies (such as visualization, navigation and powered instruments), neurotechnology and spine solutions, and patient-handling and emergency medical equipment.